1[1]Kommoss F, Karck U, Prmpeler H, et al. Steroid receptor expression in endometria from women treated with tamoxifen[J]. Gynecologic oncology, 1998,70(2):188-191.
2[2]Kim MR, Kim YA, Jo MY, et al. High frequency of endometrial polyps in endometriosis[J]. J Am Assoc Gynecol Laparosc, 2003,10(1):46-48.
3[3]Savelli L, De Iaco P, Santini D, et al. Hystopathologic features and risk factors for benignity, hyperplasia, and cancer in endometrial polyps[J]. J Am Assoc Gynecol Laparosc,2003,188(4):927-931.
4[4]Bouda J Jr, Hradecky L, Rokyta Z. Hysteroscopic polypectomy versus fractionated curettage in the treatment of corporal polyps-recurrence of corporal polyps[J]. Ceska Gynekol,2000,65(3):147-151.
5[5]Mittal K, Schwartz L, Goswami S, et al. Estrogen and progesterone receptor expression in endometrial polyps[J]. Int J Gynecol Pathol,1996,15(4):345-348.
6[6]Maia H, Maltez A, Athayde C, et al. Proliferation profile of endometrial polyps in post-menopausal women[J]. Maturitas,2001,40(3):273-281.
7[7]Tallini G , Vanni R, Ianfioletti G, et al. HMGI-C and HMGI(Y) immunoreactivity correlates with cytogenetic abnormalities in lipomas,pulmonary chondroid hamartomas,endometrial polyps,and uterine leiomyomas and is compatible with rearrangement of the HMGI-C and HMGI(Y) genes[J]. Lab Invest,2000,80(1):359-369.
8[8]Goldenberg M, Nezhat C, Seidman DS. A randomized prospective study of the use of endometrial ablation for prevention of recurrent endometrial polyps in breast cancer patients receiving tamoxifen[J]. Prim Care Update Ob Gyns,1998,5(4):160.
9[9]DeWaay DJ, Syrop CH,Nygaard IE,et al. Natural history of uterine polyps and leiomyomata[J]. Obstet Gynecol,2002,100(1):3-7.
10[10]Gardner FJ, Konje JC, Abrams KR, et al. Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system:a randomised controlled trial[J]. Lancet,2000,356(9243):1711-1717.
